On April 2, 2026 AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic CAR-T cell therapies, reported that it has dosed the first patient in the Phase I QUADvance study (AVC-203-01; NCT07284433) with AVC-203 for the treatment of relapsed/refractory B-cell malignancies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AVC-203 is a CRISPR-engineered allogeneic CAR-T candidate designed to simultaneously target and eliminate cells expressing receptors CD19 and/or CD20, which are known to be expressed in nearly all B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). The product incorporates a novel, dimerized receptor construct combining constitutive CD19/CD20 dual-targeting with AvenCell’s proprietary RevCAR switchable receptor, enabling future indication flexibility and target expansion beyond CD19/CD20 through bi- or tri-specific bridging proteins.
"Patients with relapsed/refractory B-cell malignancies who have exhausted currently available treatment options, including approved autologous CAR-T therapies, have limited alternatives and a poor prognosis," said Professor Martin Wermke, Head of the Early Clinical Trial Unit at the National Cancer Center Dresden, Germany. "AvenCell’s allogeneic approach, combined with its innovative dual-targeting and switchable technology, represents a promising new therapeutic strategy for these patients."
"Dosing the first patient with AVC-203 is a significant milestone for AvenCell and for the field of allogeneic cell therapy," said Andrew Schiermeier, AvenCell’s President & CEO. "We are excited to build on the promising safety and activity observed in our ongoing allogeneic CAR-T clinical program in AML (AVC-201-01) by now entering B-cell lymphoma with what we believe to be the most scientifically compelling allogeneic technology in the industry. AvenCell remains focused on ensuring that any patient who can benefit from CAR-T therapy can receive it, through the massive scaling of supply and dramatic reductions in cost of goods."
The AVC-203 program is supported by a grant of up to $40 million from the Japan Agency for Medical Research and Development ("AMED") (Project Name: "Strengthening Program for Pharmaceutical Startup Ecosystem" R&D Project Title: "Clinical development of bispecific allogeneic CAR-T cell therapy for CD19/CD20-positive relapsed/refractory B-cell lymphoma"), underscoring the global significance of AvenCell’s allogeneic CAR-T platform. The AMED grant will support the advancement of AVC-203 toward clinical development in Japan, with the goal of bringing this innovative therapy to patients across the Asia-Pacific region.
AvenCell received both FDA IND clearance and EMA approval of its Clinical Trial Application (CTA) for the QUADvance study on first submission in late 2025, enabling trial initiation at multiple sites in the US and Europe.
About AVC-203
AVC-203 is a CRISPR-engineered allogeneic CAR-T therapy incorporating four key innovations:
Dual antigen targeting: AVC-203 CAR-T cells express a proprietary receptor that simultaneously targets CD19 and CD20.
Immune evasion: AvenCell implements a unique, differentiated, and proprietary sequence of CRISPR/Cas9 engineering to enable the use of healthy donor cell (versus the patient’s own cells) to avoid both Graft-versus-Host Disease (GvHD) and rejection by the patient’s immune system.
Improved T-cell fitness and off-the-shelf availability: A proprietary manufacturing process leverages the highly consistent T-cell fitness of healthy donors to eliminate the cost, variability, and complexity of patient-specific production, enabling immediate, massively-scalable treatment.
Switchable targeting: A RevCAR receptor dimerized to the CD19/CD20 CAR enables flexible targeting of additional tumor antigens through bi- or tri-specific bridging proteins, allowing future target expansion beyond CD19/CD20.
About AVC-203 Clinical Program
The QUADvance study (AVC-203-01) is a Phase I/II trial evaluating the safety, tolerability, efficacy, and pharmacokinetics of AVC-203 in adults with relapsed or refractory B-cell malignancies. The study is being conducted at multiple sites in the US and Europe, with planned expansion to Japan..
About B-Cell Malignancies
B-cell malignancies — including non-Hodgkin lymphomas, multiple myeloma, and B-cell acute lymphoblastic leukemia (B-ALL) — account for the majority of blood cancers. Approximately 120,000 and 150,000 new cases are diagnosed annually in the United States and Europe, respectively. While approved autologous CAR-T therapies have demonstrated meaningful clinical activity in certain B-cell malignancies, significant challenges remain, including lengthy manufacturing timelines, high costs, and limited accessibility. Allogeneic CAR-T therapies such as AVC-203 aim to address these limitations through off-the-shelf availability, consistent product quality, and scalable manufacturing.
(Press release, AvenCell Therapeutics, APR 2, 2026, View Source [SID1234664159])